IL10 and chronic graft versus host disease: Patients with refractory chronic graft versus host disease (cGvHD) present lower frequencies of total B cells and CD5+IL-10+ B. However, after three months of MSC treatment patients showed improvement of their symptoms correlating with increased CD5+IL-10+ B cells.